Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“The FDA’s 2021 rule made it impossible to issue orders on the vast majority of applications within 180 days.”
Mostly supportedConfidence: MODERATE

Reasoning

The Reason.com article reports that Helix et al. argue the FDA's 2021 rule prevented the agency from issuing orders on most applications within the statutory 180‑day deadline, aligning with the claim. No contradictory evidence is provided.

On confidence: The claim is directly supported by a secondary source quoting experts (Helix et al.) who state the 2021 rule made timely orders impossible.

Important context

The evidence is a secondary report summarizing expert analysis, not the original FDA rule text. The claim pertains to the practical effect of the rule as interpreted by Helix et al.

Evidence

Supporting (2)

Limitations

The source is a secondary news article; the original FDA rule or direct statements from the agency are not cited, limiting verification to the reported expert opinion.

Last verified:
Oct 1, 2026, 4:41 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products

Reason · Jacob Sullum